Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume mHNPC, but Without Clear Benefit Over Enzalutamide in Biomarker-Unselected Population By Ogkologos - October 20, 2026 5 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ZZ-FIRST study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL Meet the first recipient of the ESMO Artificial Intelligence Fellowship MOST POPULAR EMA Recommends Extending Indications for Pembrolizumab to Patients with Advanced Biliary... December 1, 2023 EMA Recommends Extension of Indications for Tegafur December 24, 2021 What Is Scanxiety? How People With Cancer and Survivors Can Cope October 28, 2021 Los obstáculos en la atención para las personas LGBTQ con cáncer:... January 21, 2021 Load more HOT NEWS ESMO Welcomes European Parliament (EP) report on Psychosocial Risks (PSR) at... FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous... FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive,... Do as I say, not as I do – when the...
